The chief financial officer of Pfizer said on Wednesday data from a large trial of Schering-Plough Corp's rival Vytorin cholesterol drug could provide more clout in the marketing of Pfizer's best-selling Lipitor.
Prescriptions for Vytorin, which Schering-Plough sells in partnership with Merck, have fallen since mixed findings from the so-called ENHANCE trial of Vytorin were unveiled by the two drugmakers on Jan. 14.
Vytorin failed to prevent further buildup of fatty plaque in the carotid artery when compared with simvastatin alone during the two-year study.
"It allows us to make our case the way we've been making it, and quite frankly gives it more teeth in terms of the clinical impact of our product," Pfizer Chief Financial Officer Frank D'Amelio told Reuters in an interview.
"Our product is proven not only to reduce 'bad' LDL cholesterol, but also to reduce plaque in arteries," D'Amelio said. "These other (Vytorin) clinical results clearly don't hurt us; they allow us to make our points about our product."
Hey Skip and Lee!
Prescriptions for Vytorin, which Schering-Plough sells in partnership with Merck, have fallen since mixed findings from the so-called ENHANCE trial of Vytorin were unveiled by the two drugmakers on Jan. 14.
Vytorin failed to prevent further buildup of fatty plaque in the carotid artery when compared with simvastatin alone during the two-year study.
"It allows us to make our case the way we've been making it, and quite frankly gives it more teeth in terms of the clinical impact of our product," Pfizer Chief Financial Officer Frank D'Amelio told Reuters in an interview.
"Our product is proven not only to reduce 'bad' LDL cholesterol, but also to reduce plaque in arteries," D'Amelio said. "These other (Vytorin) clinical results clearly don't hurt us; they allow us to make our points about our product."
Hey Skip and Lee!
Would you care to reconsider your recent words on Son of Whytorin !
A Lipitor/ezetemibe combo!
LOL
Oh. And while we are on the "combo" theme.
Insider suspects the "Son of Crestor" Abbott/AstraZeneca team will be having some interesting meetings at the moment! Insider wonders what data the FDA might now want to approve such combos in a post- ENHANCE world!
ROFL
No comments:
Post a Comment